Dr Pepper Snapple Group (DPS) Holder Matarin Capital Management Raised Its Position by $2.23 Million; Crestwood Advisors Has Lowered Its Cvs Health Com (CVS) Holding by $2.88 Million

April 23, 2018 - By Peter Erickson

CVS Health Corporation (NYSE:CVS) Logo

Matarin Capital Management Llc increased its stake in Dr Pepper Snapple Group Inc. (DPS) by 0.06% based on its latest 2017Q4 regulatory filing with the SEC. Matarin Capital Management Llc bought 23 shares as the company’s stock rose 23.05% while stock markets declined. The institutional investor held 38,599 shares of the consumer non-durables company at the end of 2017Q4, valued at $3.75B, up from 38,576 at the end of the previous reported quarter. Matarin Capital Management Llc who had been investing in Dr Pepper Snapple Group Inc. for a number of months, seems to be bullish on the $21.57B market cap company. The stock decreased 0.27% or $0.32 during the last trading session, reaching $120. About 393,988 shares traded. Dr Pepper Snapple Group, Inc. (NYSE:DPS) has risen 21.65% since April 23, 2017 and is uptrending. It has outperformed by 10.10% the S&P500.

Crestwood Advisors Llc decreased its stake in Cvs Health Corp Com (CVS) by 16.78% based on its latest 2017Q4 regulatory filing with the SEC. Crestwood Advisors Llc sold 40,009 shares as the company’s stock declined 17.45% with the market. The institutional investor held 198,433 shares of the medical and nursing services company at the end of 2017Q4, valued at $14.39 million, down from 238,442 at the end of the previous reported quarter. Crestwood Advisors Llc who had been investing in Cvs Health Corp Com for a number of months, seems to be less bullish one the $66.69 billion market cap company. The stock increased 0.75% or $0.49 during the last trading session, reaching $65.61. About 3.11 million shares traded. CVS Health Corporation (NYSE:CVS) has declined 22.81% since April 23, 2017 and is downtrending. It has underperformed by 34.36% the S&P500.

Among 21 analysts covering Dr Pepper Snapple (NYSE:DPS), 10 have Buy rating, 0 Sell and 11 Hold. Therefore 48% are positive. Dr Pepper Snapple had 76 analyst reports since July 21, 2015 according to SRatingsIntel. RBC Capital Markets maintained the shares of DPS in report on Friday, June 9 with “Hold” rating. UBS maintained it with “Neutral” rating and $99 target in Friday, July 28 report. The firm has “Outperform” rating by RBC Capital Markets given on Monday, March 19. The stock of Dr Pepper Snapple Group, Inc. (NYSE:DPS) has “Hold” rating given on Wednesday, January 31 by BMO Capital Markets. The stock has “Hold” rating by Cowen & Co on Monday, January 8. The rating was maintained by Stifel Nicolaus on Thursday, August 31 with “Buy”. Cowen & Co maintained it with “Hold” rating and $9600 target in Thursday, July 13 report. The firm earned “Buy” rating on Friday, March 3 by Jefferies. The stock of Dr Pepper Snapple Group, Inc. (NYSE:DPS) has “Buy” rating given on Tuesday, February 6 by Barclays Capital. The rating was maintained by Jefferies with “Buy” on Monday, September 11.

Matarin Capital Management Llc, which manages about $198.00M and $1284.49B US Long portfolio, decreased its stake in Union Bankshares Corporation (NASDAQ:UBSH) by 67,457 shares to 20,867 shares, valued at $754.76 million in 2017Q4, according to the filing. It also reduced its holding in Home Bancshares Inc. (NASDAQ:HOMB) by 40,834 shares in the quarter, leaving it with 247,088 shares, and cut its stake in Celgene Corporation (NASDAQ:CELG).

Since February 16, 2018, it had 0 buys, and 1 sale for $1.42 million activity.

Among 26 analysts covering CVS Health (NYSE:CVS), 19 have Buy rating, 0 Sell and 7 Hold. Therefore 73% are positive. CVS Health had 76 analyst reports since July 22, 2015 according to SRatingsIntel. On Thursday, December 17 the stock rating was maintained by Oppenheimer with “Outperform”. RBC Capital Markets maintained CVS Health Corporation (NYSE:CVS) rating on Monday, December 4. RBC Capital Markets has “Buy” rating and $95.0 target. Goldman Sachs downgraded CVS Health Corporation (NYSE:CVS) on Thursday, December 17 to “Neutral” rating. The company was maintained on Tuesday, January 2 by Needham. On Monday, August 14 the stock rating was downgraded by Wolfe Research to “Peer Perform”. Jefferies maintained CVS Health Corporation (NYSE:CVS) rating on Tuesday, November 7. Jefferies has “Hold” rating and $76 target. Needham upgraded the stock to “Buy” rating in Tuesday, January 30 report. The firm earned “Neutral” rating on Tuesday, February 13 by Citigroup. On Friday, September 8 the stock rating was maintained by Needham with “Hold”. The firm has “Neutral” rating by Citigroup given on Monday, May 9.

Investors sentiment decreased to 0.72 in 2017 Q4. Its down 0.16, from 0.88 in 2017Q3. It dropped, as 115 investors sold CVS shares while 600 reduced holdings. 134 funds opened positions while 380 raised stakes. 815.59 million shares or 1.76% more from 801.45 million shares in 2017Q3 were reported. Lyons Wealth Limited Com invested in 1.34% or 11,307 shares. 1.02 million are held by Gabelli Funds Ltd. Westpac Bk Corporation holds 0.11% of its portfolio in CVS Health Corporation (NYSE:CVS) for 66,195 shares. West Oak Cap Ltd Liability Com invested 0.88% of its portfolio in CVS Health Corporation (NYSE:CVS). First Western Capital Mngmt reported 38,891 shares or 1.6% of all its holdings. Northcoast Asset Lc holds 36,010 shares or 0.23% of its portfolio. 607,506 were reported by Fil Ltd. Whalerock Point Ptnrs Ltd Liability Co holds 0.64% or 28,051 shares. Utd Service Automobile Association has invested 0.23% in CVS Health Corporation (NYSE:CVS). Oarsman Capital Inc, Wisconsin-based fund reported 40,422 shares. 144,771 are held by Calamos Limited Com. Martin And Inc Tn reported 19,120 shares stake. Osborne Prtn Mgmt Ltd holds 0.88% or 92,099 shares in its portfolio. Patten Gp Inc stated it has 0.07% in CVS Health Corporation (NYSE:CVS). Hanson & Doremus Inv Mngmt owns 1,384 shares or 0.03% of their US portfolio.

CVS Health Corporation (NYSE:CVS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: